Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-17T00:17:48.420Z Has data issue: false hasContentIssue false
  • English
  • Français

Introduction: Cardiovascular Disease and Metabolic Risk Factors in Patients with Mental Illness

Published online by Cambridge University Press:  07 November 2014

John W. Newcomer
Get access Rights & Permissions [Opens in a new window]

Extract

According to the National Comorbidity Study Replication, >25% of people in the United States have some type of mental illness. The prevalence of serious mental illness has been estimated at 6.2%. Patients with severe and persistent mental illness have significantly reduced life expectancy relative to the general population. On average, pooled populations of public sector inpatients and outpatients die 25–30 years earlier than unaffected individuals in the general population, according to recent data from multiple states in the US. Schizophrenia and bipolar disorder together account for ∼23,000 deaths and >20 million life-years of disability worldwide each year. The most common cause of mortality in these individuals is cardiovascular disease (CVD), not, as might be assumed, suicide (Figure 1). Heart disease and stroke are the most common causes of death in patients with serious mental illness, accounting for ∼40% of deaths, underlying the dramatically decreased life expectancy in these patients.

Type
Clinical Information Supplement
Information
CNS Spectrums , Volume 13 , supplement S10: Elevating the Standard of Care in the Management of Cardiometabolic Risk Factors in Patients with Mental Illness , June 2008 , pp. 3 - 4
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Kessler, RC, Chiu, WT, Demler, O, Merikangas, KR, Walters, EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627.CrossRefGoogle ScholarPubMed
2. Kessler, RC, Berglund, PA, Bruce, ML, et al. The prevalence and correlates of untreated serious mental illness. Health Serv Res. 2001;36(6 pt 1):987–1007.Google ScholarPubMed
3. Colton, CW, Manderscheid, RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):A42.Google ScholarPubMed
4. Lopez, AD, Mathers, CD, Ezzati, M, Jamison, DT, Murray, CJL. Global Burden of Disease and Risk Factors, 2006. Disease Control Priorities Project and the International Bank for Reconstruction and Development, The World Bank, the World Health Organization, and the Fogarty International Center of the National Institutes of Health. Available at: http://files.dcp2.org/pdf/GBD/GBD.pdf. Accessed November 15, 2007.CrossRefGoogle Scholar
5. Meyer, JM, Nasrallah, HA, eds. Medical Illness and Schizophrenia. Washington, DC: American Psychiatric Publishing; 2003.Google Scholar
6. Patel, VB, Robbins, MA, Topol, EJ. C-reactive protein: a ‘golden marker’ for inflammation and coronary artery disease. Cleve Clin J Med. 2001;68(6):521–534.CrossRefGoogle ScholarPubMed
7. Carr, LL. Summary of the role of statins in the treatment of dyslipidemia. J Am Osteopath Assoc. 2003;103(7 suppl 3):S1–S3.Google ScholarPubMed
8. Lambert, TJ, Velakoulis, D, Pantelis, C. Medical comorbidity in schizophrenia. Med J Aust. 2003;178 (suppl):S67–S70.CrossRefGoogle ScholarPubMed
9. Marder, SR, Essock, SM, Miller, AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334–1349.CrossRefGoogle ScholarPubMed
10. Newcomer, JW. Metabolic risk during antipsychotic treatment. Clin Ther. 2004;26(12):1936–1946.CrossRefGoogle ScholarPubMed
11. Newcomer, JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1–93.CrossRefGoogle ScholarPubMed
12. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267–272.CrossRefGoogle Scholar
13. Cuffel, B, Martin, J, Joyce, A, Boccuzzi, S, Loebel, A. Lipid and glucose monitoring during atypical antipsychotic treatment: effect of 2004 ADA/APA consensus statement. Presented at: 159th Annual Meeting of the American Psychiatric Association; May 20–25, 2006; Toronto, Canada.Google Scholar
14. Parks, J, Svendsen, D, Singer, P, Foti, ME. Morbidity and mortality in people with serious mental illness. Thirteenth in a series of technical reports. Association of State Mental Health Program Directors (NASMHPD). Available at: http://www.nasmhpd.org/general_files/publications/med_directors_pubs/Technical%20Report%20on%20Morbidity%20and%20Mortaility%20-%20Final%2011–06.pdf. Accessed May 22, 2008.Google Scholar